Breaking Ground: A Review of Brenzavvy - The newly approved treatment for type 2 Diabetes mellitus Namdev Ruchika*, Joshi Deepak, Jain Vikas, Sharma Ajay Mahakal Institute of Pharmaceutical Studies, Ujjain, 456664, Madhya Pradesh, India *Corresponding Author E-mail: ruchikanamdev2001@gmail.com
Online Published on 23 April, 2025. Abstract Type 2 diabetes mellitus (T2DM) is a persistent metabolic condition defined by insulin resistance and relative insulin insufficiency, frequently worsened by lifestyle elements. Brenzavvy, also known as Bexagliflozin, is a recently authorized medication tailored for managing T2DM. Its approval in the United States on January 20, 2023, marks it as an sodium-glucose co-transporter 2 inhibitor. This novel drug functions by inhibiting the sodium-glucose co-transporter 2, thereby enhancing glucose excretion in urine and reducing blood sugar levels. This review delves into Brenzavvy ’s pharmacological attributes, clinical effectiveness, safety profile, and potential implications for T2DM treatment. Clinical trials have illustrated its efficacy in ameliorating glycemic control in T2DM patients, coupled with added advantages such as weight and blood pressure reduction. Overall, Brenzavvy represents a promising addition to the armamentarium of T2DM management, offering a novel approach to address hyperglycemia and associated metabolic abnormalities. Continued research and monitoring will further elucidate its role in enhancing patient outcomes and quality of life in the management of T2DM. Top Keywords Type 2 diabetes mellitus, SGLT2, Glucose, Brenzavvy, Renal excretion. Top |